

Michael Medinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7385424/publications.pdf>

Version: 2024-02-01

70
papers

1,104
citations

471061

17
h-index

454577

30
g-index

70
all docs

70
docs citations

70
times ranked

1986
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 224-231.	1.3	5
2	Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogeneic stem cell transplantation with prophylactic ursodiol and low-dose heparin. <i>Bone Marrow Transplantation</i> , 2022, 57, 391-398.	1.3	5
3	Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study. <i>Bone Marrow Transplantation</i> , 2022, 57, 613-619.	1.3	7
4	Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 903-910.	1.3	11
5	External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study. <i>HemaSphere</i> , 2022, 6, e704.	1.2	2
6	CBâ€œ103: A novel CSLâ€œNICD inhibitor for the treatment of NOTCHâ€œdriven Tâ€œcell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory Tâ€œALL. <i>EJHaem</i> , 2022, 3, 1009-1012.	0.4	13
7	Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1171-1179.	1.3	30
8	Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial. <i>Annals of Hematology</i> , 2021, 100, 209-216.	0.8	13
9	Does the order of busulfan and cyclophosphamide affect allogeneic stem cell transplantation related liver toxicity?. <i>Annals of Hematology</i> , 2021, 100, 1349-1350.	0.8	0
10	Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. <i>Annals of Hematology</i> , 2021, 100, 1169-1179.	0.8	5
11	Lack of association of travel time to transplant center and posttransplant care model with outcome parameters after allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2024-2026.	1.3	0
12	Incidence and impact of Epstein-Barr virus events in the early phase after allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 1913-1915.	0.8	0
13	Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 2011-2015.	0.3	1
14	Influence of HLA-DPB1 mismatches on outcome after allogeneic hematopoietic stem cell transplantation. <i>Leukemia Research Reports</i> , 2021, 16, 100259.	0.2	1
15	Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. <i>Medical Mycology</i> , 2021, 59, 701-711.	0.3	8
16	Peripheral blood schistocytes in the acute phase after allogeneic or autologous stem cell transplantation assessed by digital microscopy. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 145-151.	0.7	3
17	Optimal Treatment Duration of <i>Pseudomonas aeruginosa</i> Infections in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa246.	0.4	7
18	Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation â€œ A Single Centre Study. <i>Anticancer Research</i> , 2020, 40, 5909-5917.	0.5	12

#	ARTICLE	IF	CITATIONS
19	New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation. <i>In Vivo</i> , 2020, 34, 3545-3549.	0.6	8
20	Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best perceived in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host disease in gastrointestinal biopsies. <i>Bone Marrow Transplantation</i> , 2020, 55, 1847-1850.	1.3	9
21	Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study. <i>Transplant Infectious Disease</i> , 2020, 22, e13289.	0.7	11
22	Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor – A multicenter analysis. <i>American Journal of Transplantation</i> , 2019, 19, 475-487.	2.6	14
23	Baseline calprotectin fails to predict incidence of acute gastrointestinal graft vs. host disease: a prospective study. <i>Bone Marrow Transplantation</i> , 2019, 54, 343-347.	1.3	0
24	High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2019, 54, 540-548.	1.3	49
25	Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient. <i>Frontiers in Pharmacology</i> , 2019, 10, 645.	1.6	8
26	Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. <i>Annals of Hematology</i> , 2019, 98, 1485-1493.	0.8	27
27	Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1651-1661.	1.3	15
28	Cyclosporine levels $\geq 195 \text{ ng/L}$ on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 971-977.	0.8	17
29	Transient focal neurologic deficits upon hematopoietic stem cell transplantation: just a coincidence?. <i>Acta Neurologica Belgica</i> , 2019, 119, 129-131.	0.5	0
30	Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 184, 294-298.	1.2	7
31	Stress and catecholamines modulate the bone marrow microenvironment to promote tumorigenesis. <i>Cell Stress</i> , 2019, 3, 221-235.	1.4	23
32	Impact of Amotosalen/UVA Pathogen Inactivated Platelet Components on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Analysis. <i>Blood</i> , 2019, 134, 1167-1167.	0.6	1
33	Beneficial role of increased FOXP3^+ regulatory T cells in acute myeloid leukaemia therapy response. <i>British Journal of Haematology</i> , 2018, 182, 581-583.	1.2	8
34	Pathogenesis of Acquired Aplastic Anemia and the Role of the Bone Marrow Microenvironment. <i>Frontiers in Oncology</i> , 2018, 8, 587.	1.3	49
35	What the internist should know about stem cell transplant in the elderly patient. <i>European Journal of Internal Medicine</i> , 2018, 58, 43-47.	1.0	0
36	Severe anemia after trans-catheter arterial chemoembolization – an unusual presentation of hemoglobin Zurich. <i>Annals of Hematology</i> , 2018, 97, 2249-2251.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study. <i>Transplant Infectious Disease</i> , 2018, 20, e12981.	0.7	35
38	Red Blood Cell Allo-Antibodies after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2551-2551.	0.6	1
39	Haploidentical hematopoietic bone marrow transplantation followed by living kidney transplantation from the same donor in a sickle cell disease patient with end-stage renal failure. <i>Annals of Hematology</i> , 2017, 96, 703-705.	0.8	9
40	Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice. <i>Haematologica</i> , 2017, 102, 854-864.	1.7	25
41	Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 58, 43-47.	0.4	19
42	Fungemia and necrotic lymph node infection with <i>Sporopachydermia cereana</i> in a patient with acute myeloid leukemia. <i>International Journal of Infectious Diseases</i> , 2017, 61, 103-106.	1.5	2
43	Acute myeloid leukaemia genomics. <i>British Journal of Haematology</i> , 2017, 179, 530-542.	1.2	82
44	Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 927-930.	1.1	11
45	Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. <i>Leukemia Research</i> , 2016, 47, 22-25.	0.4	8
46	Novel therapeutic options in Acute Myeloid Leukemia. <i>Leukemia Research Reports</i> , 2016, 6, 39-49.	0.2	30
47	Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2016, 95, 1627-1636.	0.8	8
48	Reactive Hemophagocytic Syndrome after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). <i>Blood</i> , 2016, 128, 4617-4617.	0.6	1
49	Molecular Risk Stratification Predicts Engraftment Latency of Human Acute Myeloid Leukemia Cells Transplanted in NOD/SCID/IL-2Rgc-Null Mice. <i>Blood</i> , 2016, 128, 2867-2867.	0.6	0
50	Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. <i>Cancer Genomics and Proteomics</i> , 2016, 13, 317-29.	1.0	22
51	Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents. <i>Cancer Genomics and Proteomics</i> , 2016, 13, 275-9.	1.0	1
52	Angiogenic markers in plasma cell myeloma patients treated with novel agents. <i>Anticancer Research</i> , 2015, 35, 1085-90.	0.5	8
53	Dkk3 levels in patients with myeloproliferative neoplasms. <i>Thrombosis Research</i> , 2014, 133, 218-221.	0.8	2
54	Intra-arterial catheter guided steroid administration for the treatment of steroid-refractory intestinal GvHD. <i>Leukemia Research</i> , 2014, 38, 184-187.	0.4	11

#	ARTICLE	IF	CITATIONS
55	Evaluation of the Pretransplantation Workup before Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1852-1856.	2.0	9
56	Angiogenesis in myeloproliferative neoplasms, new markers and future directions. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 206-210.	0.3	26
57	Role of tumour angiogenesis in haematological malignancies. <i>Swiss Medical Weekly</i> , 2014, 144, w14050.	0.8	35
58	Evaluation Of The Pre-Transplantation Workup Before Allogeneic Transplantation and Reasons For Delaying Or Cancelling Transplant. <i>Blood</i> , 2013, 122, 5456-5456.	0.6	1
59	Intra-Arterial Catheter Guided Steroid Administration For The Treatment Of Steroid-Refractory Intestinal GvHD. <i>Blood</i> , 2013, 122, 4604-4604.	0.6	0
60	Aplastic anemia in association with a lymphoproliferative neoplasm: Coincidence or causality?. <i>Leukemia Research</i> , 2012, 36, 250-251.	0.4	9
61	Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms. <i>Thrombosis and Haemostasis</i> , 2011, 105, 72-80.	1.8	14
62	A Rare Case of Coinheritance of Hemoglobin H Disease and Sickle Cell Trait Combined with Severe Iron Deficiency. <i>Hematology Reports</i> , 2011, 3, e30.	0.3	3
63	c-kit (CD117) Expression in Human Tumors and its Prognostic Value: An Immunohistochemical Analysis. <i>Pathology and Oncology Research</i> , 2010, 16, 295-301.	0.9	33
64	Clinical trials with anti-angiogenic agents in hematological malignancies. <i>Journal of Angiogenesis Research</i> , 2010, 2, 10.	2.9	29
65	Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies. <i>Journal of Oncology</i> , 2010, 2010, 1-13.	0.6	42
66	Angiogenesis and vascular endothelial growth factor receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2 V617F mutational status. <i>British Journal of Haematology</i> , 2009, 146, 150-157.	1.2	76
67	Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma. <i>Anticancer Research</i> , 2009, 29, 5065-76.	0.5	15
68	Late Altered Organ Function in Long Term Survivors after Allogeneic HSCT: A Paired Comparison with Their Identical Sibling Donor. <i>Blood</i> , 2008, 112, 4298-4298.	0.6	2
69	Chronic GVHD Leads to Shortening of Telomeres in Subsets of Lymphoid Cells but Not in Granulocytes in Long-Term Survivors after Allogeneic HSCT. <i>Blood</i> , 2006, 108, 2872-2872.	0.6	0
70	Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. <i>European Journal of Cancer</i> , 2005, 41, 1291-1299.	1.3	166